What is the management of Transfusion-Related Acute Lung Injury (TRALI) after Blood Transfusion (BT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Transfusion-Related Acute Lung Injury (TRALI)

Stop the transfusion immediately and provide aggressive respiratory support with 100% oxygen—do NOT give diuretics, as TRALI is non-cardiogenic pulmonary edema requiring critical care supportive measures, not volume removal. 1, 2

Immediate Actions (First 5 Minutes)

  • Discontinue the transfusion immediately and maintain IV access with normal saline for medication administration and potential fluid resuscitation 1, 3
  • Administer 100% high-flow oxygen to address the severe hypoxemia that characterizes TRALI 1, 3
  • Call for help immediately and prepare for potential intubation and mechanical ventilation, as many patients will require mechanical ventilatory support 1
  • Maintain blood pressure with IV fluid resuscitation using normal saline or lactated Ringer's solution to support organ perfusion (MAP >65-70 mmHg) 1, 3
  • Monitor vital signs every 5-15 minutes, including heart rate, blood pressure, temperature, respiratory rate, and oxygen saturation 3

Critical Diagnostic Distinction

The presence of hypotension (not hypertension) is the key feature that distinguishes TRALI from Transfusion-Associated Circulatory Overload (TACO). 1, 3

  • TRALI presents with hypoxemia, dyspnea, hypotension, and bilateral pulmonary infiltrates within 1-6 hours of transfusion 4, 1, 2
  • TACO presents with hypertension, cardiovascular changes suggesting fluid overload, and responds to diuretics 1, 3
  • Never administer diuretics for TRALI—they are ineffective and potentially harmful, as this is non-cardiogenic pulmonary edema requiring supportive care, not volume removal 1, 2, 3

Respiratory Support Algorithm

  • Provide supplemental oxygen immediately with target SpO2 >90% 1, 3
  • Prepare for intubation if the patient shows signs of respiratory failure: inability to maintain oxygenation on high-flow oxygen, altered mental status, or respiratory exhaustion 1
  • In mechanically ventilated patients, monitor peak airway pressure as it will be elevated 4, 2
  • Most patients require mechanical ventilation for 2-4 days, with clinical improvement typically beginning within the first few hours and complete resolution within 96 hours 5, 6, 7

Laboratory Workup

  • Send post-reaction blood samples immediately for complete blood count, direct antiglobulin test (Coombs test), repeat crossmatch, PT, aPTT, and fibrinogen to exclude hemolytic reaction 1, 3
  • Visual inspection of plasma for hemolysis should be performed 3
  • These tests help exclude other transfusion reactions that may present similarly 1, 3

Mandatory Reporting

  • Report the reaction to the blood bank immediately—this is critical to remove the implicated donor from the pool and prevent future TRALI reactions in other patients 1, 2, 3
  • TRALI is the leading cause of transfusion-related mortality but remains underdiagnosed and underreported 4, 1, 8, 9
  • The blood bank will test the donor serum for HLA class I, class II, or granulocyte-specific antibodies, which are found in 65-89% of TRALI cases 1, 7

Ongoing Management

  • Continue observation for at least 24 hours, as TRALI can evolve over the first 6-12 hours post-transfusion 1
  • Provide critical care supportive measures focusing on respiratory support and maintaining adequate perfusion 4, 2
  • Maintain appropriate fluid balance without overhydration, as excessive fluids can worsen pulmonary edema 2
  • Avoid additional transfusions unless absolutely necessary for life-threatening hemorrhage 2

Pathophysiology and Prognosis

  • TRALI is caused by donor leukocyte antibodies (HLA class I, class II, or granulocyte-specific) interacting with recipient neutrophils, causing granulocyte aggregation and complement activation in lung capillaries 4, 1, 9
  • Fresh frozen plasma (FFP) and platelet concentrates are the blood products most frequently implicated, as they contain significant plasma volumes 2, 3
  • Mortality rate is 5-14%, making TRALI the leading cause of transfusion-related deaths 8, 6
  • 80% of patients recover within 96 hours with appropriate respiratory intervention, with no permanent pulmonary sequelae 6, 7

Common Pitfalls to Avoid

  • Do not give diuretics—the single most dangerous error is treating TRALI as fluid overload (TACO), as diuretics are ineffective and potentially harmful 1, 2, 3
  • Do not delay reporting to the blood bank—early identification of implicated donors prevents future reactions in other patients 1, 2, 8
  • Do not confuse fever with infection—fever is a common feature of TRALI and does not necessarily indicate bacterial contamination 4

References

Guideline

Diagnosis and Management of Transfusion-Related Acute Lung Injury (TRALI)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Transfusion-Related Acute Lung Injury (TRALI)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Transfusion-Related Complications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A suspected case of transfusion-related acute lung injury.

Lung India : official organ of Indian Chest Society, 2011

Research

Transfusion and lung injury.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2001

Research

Case report: transfusion-related acute lung injury (TRALI) - a clear and present danger.

Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2007

Related Questions

What is the treatment for Transfusion-Related Acute Lung Injury (TRALI)?
What is the typical duration of post-transfusion related Transfusion-Related Acute Lung Injury (TRALI)?
What is the management of Transfusion-Related Acute Lung Injury (TRALI)?
What are the criteria and management for Transfusion-Related Acute Lung Injury (TRALI)?
What is the treatment for suspected Transfusion-Related Acute Lung Injury (TRALI)?
What is the reason for the increase in bicarbonate level to >40 in a patient with a history of Chronic Obstructive Pulmonary Disease (COPD) on 4 L oxygen, combined systolic and diastolic heart failure, non-ischemic cardiomyopathy, and non-obstructive coronary artery disease, who was admitted for acute on chronic heart failure and started on Lasix (furosemide) infusion with a baseline bicarbonate level of 38-39?
What is the recommended treatment for a patient with type 2 diabetes and a history of cardiovascular disease, considering glycemic control and potential complications like heart failure and impaired renal function?
What is the appropriate treatment regimen for a 9-year-old patient with gastrointestinal symptoms, considering the use of loperamide (anti-diarrheal medication) and ondansetron (antiemetic medication)?
What are the pros and cons of decreasing sertraline (Selective Serotonin Reuptake Inhibitor) from 150mg to 125mg in a patient with Autism Spectrum Disorder (ASD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), and Attention Deficit Hyperactivity Disorder (ADHD), currently taking buspirone (Anxiolytic) 15mg, Qelbree (Viloxazine) 150mg, and guanfacine (Alpha-2 Adrenergic Agonist) ER 3mg, who previously experienced anhedonia on 100mg sertraline and now experiences sexual dysfunction, fatigue, restlessness, insomnia, and emotional blunting?
What are the signs of dehydration in individuals, particularly the elderly, young children, and those with chronic illnesses like diabetes or kidney disease?
What is the recommended treatment for a pediatric patient with Hepatitis C (HCV)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.